Eisai announces Phase Ib trial results of lenvatinib with pembrolizumab in selected solid tumours

Eisai has announced the results of a Phase Ib clinical trial of its multiple-receptor, tyrosine kinase inhibitor lenvatinib mesylate (lenvatinib) in combination with the anti-PD-1 antibody pembrolizumab developed by Merck& Co in patients with select …

Source: Drug Development Technology - October 13, 2016 Category: Pharmaceuticals Source Type: news